Therefore, therapies of pancreatic cancer using specific GP inhibitors may improve host glucose status and insulin sensitivity via improving skeletal muscle glycogen synthesis and glycogen storage, while inhibiting tumour cell proliferation and glucose cycling through glycogen. Here, INS is linked to familial pancreatic carcinoma.